TP53 and acute myeloid leukemia: In concordance with previous reports that have characterized the mutational landscape of TP53 in MDS [30] and AML [33,34], we found that the majority of TP53 mutations occur in residues within the DNA-binding domain (Figure 4B), with particular enrichment for g.7577538 C>T/g.7577539 G>A/C (p.R248W/Q/G; n = 6), g.7578190 T>C (p.Y220C; n = 3), and g.7577120 C>T/A (p.R273H/L; n = 3).